Recently, several replicating studies have shown that dose adjustment based on presence of low activity NUDT15 variant (Arg139Cys) should be made in children receiving 6MP for treatment of ALL [120,122,123,125,126]. This evidence concerns the gene NUDT15 and acute lymphoblastic leukemia.